Clinical Trial Detail

NCT ID NCT04452214
Title A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cantargia AB
Indications

transitional cell carcinoma

head and neck squamous cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

Nidanilimab + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.